Editorial
Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern

https://doi.org/10.1016/j.jaapos.2009.06.003Get rights and content

References (24)

  • T.A. Ciulla et al.

    Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration

    Curr Opin Ophthalmol

    (2009)
  • J. Gaudreault et al.

    Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

    Invest Ophthalmol Vis Sci

    (2005)
  • Cited by (0)

    See accompanying report on pages 400-402.

    Dr. Avery has received consulting or speaking fees from Alcon, Allergan, Genentech, Novartis, and Pfizer.

    View full text